Sana Biotechnology Quarterly Income Statements Chart
Quarterly
|
Annual
Sana Biotechnology Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | |||||||||||||||||
| research and development | 29,761,000 | 37,189,000 | 47,036,000 | 53,206,000 | 60,874,000 | 56,448,000 | 63,000,000 | 65,613,000 | 73,044,000 | 67,166,000 | 63,921,000 | 76,735,000 | 72,689,000 | 108,505,000 | 53,245,000 | 168,930,000 | |
| research and development related success payments and contingent consideration | 10,262,000 | 1,957,000 | -13,447,000 | -5,497,000 | -27,944,000 | 38,007,000 | 6,835,000 | -82,615,000 | 26,679,000 | 120,000 | -5,454,000 | -6,062,000 | -55,438,000 | -9,905,000 | 16,753,000 | ||
| general and administrative | 10,341,000 | 11,484,000 | 17,277,000 | 14,052,000 | 16,442,000 | 16,269,000 | 20,784,000 | 19,183,000 | 16,566,000 | 16,766,000 | 23,321,000 | 15,514,000 | 14,434,000 | 12,679,000 | 13,433,000 | 11,821,000 | |
| impairment of long-lived assets | 44,611,000 | ||||||||||||||||
| total operating expenses | 94,975,000 | 50,630,000 | 50,866,000 | 61,761,000 | 49,372,000 | 110,724,000 | 90,619,000 | 2,181,000 | 116,289,000 | 84,052,000 | 81,788,000 | 86,187,000 | 31,685,000 | 111,279,000 | 83,431,000 | 180,751,000 | |
| income from operations | -94,975,000 | -50,630,000 | -50,866,000 | -61,761,000 | -49,372,000 | -110,724,000 | -90,619,000 | -2,181,000 | -116,289,000 | -84,052,000 | -81,788,000 | -86,187,000 | -31,685,000 | -111,279,000 | -83,431,000 | -180,751,000 | |
| yoy | 92.37% | -54.27% | -43.87% | 2731.77% | -57.54% | 31.73% | 10.80% | -97.47% | 267.02% | -24.47% | -1.97% | -52.32% | |||||
| qoq | 87.59% | -0.46% | -17.64% | 25.09% | -55.41% | 22.19% | 4054.93% | -98.12% | 38.35% | 2.77% | -5.10% | 172.01% | -71.53% | 33.38% | -53.84% | ||
| operating margin % | |||||||||||||||||
| interest income | 577,000 | 992,000 | 1,656,000 | 2,579,000 | 3,202,000 | 3,034,000 | 2,726,000 | 2,862,000 | 2,374,000 | 1,976,000 | 1,613,000 | 1,173,000 | 339,000 | 267,000 | 158,000 | 121,000 | |
| other income | 598,000 | 249,000 | 141,000 | -742,000 | -4,121,000 | 215,000 | -224,000 | 303,000 | -84,000 | -47,000 | -268,000 | -106,000 | -102,000 | 281,000 | 10,000 | 13,000 | |
| net income | -93,800,000 | -49,389,000 | -49,069,000 | -59,924,000 | -50,291,000 | -107,475,000 | -88,117,000 | 984,000 | -113,999,000 | -82,123,000 | -80,443,000 | -85,120,000 | -31,448,000 | -110,731,000 | -83,263,000 | -180,617,000 | |
| yoy | 86.51% | -54.05% | -44.31% | -6189.84% | -55.88% | 30.87% | 9.54% | -101.16% | 262.50% | -25.84% | -3.39% | -52.87% | |||||
| qoq | 89.92% | 0.65% | -18.11% | 19.15% | -53.21% | 21.97% | -9054.98% | -100.86% | 38.81% | 2.09% | -5.49% | 170.67% | -71.60% | 32.99% | -53.90% | ||
| net income margin % | |||||||||||||||||
| net income per common share – basic and diluted | -390 | -210 | -210 | -490 | -590 | -430 | |||||||||||
| weighted-average number of common shares – basic and diluted | 238,409,000 | 237,578,000 | 230,891,000 | 234,440,000 | 217,290,000 | 194,541,000 | 192,540,000 | 191,228,000 | |||||||||
| net income per common share – basic | -237.5 | -250 | -252.5 | 0 | |||||||||||||
| weighted-average number of common shares – basic | 235,412,000 | 196,978,000 | |||||||||||||||
| net income per common share – diluted | -237.5 | -250 | -252.5 | 0 | |||||||||||||
| weighted-average number of common shares – diluted | 235,412,000 | 200,473,000 | |||||||||||||||
| net income per common share - basic and diluted | -420 | -450 | -170 | -610 | -460 | ||||||||||||
| weighted-average number of common shares - basic and diluted | 188,344,000 | 189,303,000 | 185,955,000 | 166,433,000 | 181,827,000 | ||||||||||||
| net income per share | -1.52 | ||||||||||||||||
| weighted-average shares outstanding, basic and diluted | 119,131 |
We provide you with 20 years income statements for Sana Biotechnology stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sana Biotechnology stock. Explore the full financial landscape of Sana Biotechnology stock with our expertly curated income statements.
The information provided in this report about Sana Biotechnology stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.